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Abstract
Background: The evolution of drug resistance in malaria parasites highlights a need to identify and evaluate
strategies that could extend the useful therapeutic life of anti-malarial drugs. Such strategies are deployed to best
effect before resistance has emerged, under conditions of great uncertainty.
Methods: Here, the emergence and spread of resistance was modelled using a hybrid framework to evaluate
prospective strategies, estimate the time to drug failure, and weigh uncertainty. The waiting time to appearance
was estimated as the product of low mutation rates, drug pressure, and parasite population sizes during treatment.
Stochastic persistence and the waiting time to establishment were simulated as an evolving branching process.
The subsequent spread of resistance was simulated in simple epidemiological models.
Results: Using this framework, the waiting time to the failure of artemisinin combination therapy (ACT) for malaria
was estimated, and a policy of multiple first-line therapies (MFTs) was evaluated. The models quantify the effects of
reducing drug pressure in delaying appearance, reducing the chances of establishment, and slowing spread. By
using two first-line therapies in a population, it is possible to reduce drug pressure while still treating the full
complement of cases.
Conclusions: At a global scale, because of uncertainty about the time to the emergence of ACT resistance, there
was a strong case for MFTs to guard against early failure. Our study recommends developing operationally feasible
strategies for implementing MFTs, such as distributing different ACTs at the clinic and for home-based care, or
formulating different ACTs for children and adults.
Background
Plasmodium falciparum, which causes malaria, is the
most important parasite species that infects humans
with approximately 2.37 billion people at risk [1,2].
Prompt effective drug treatment can reduce the risk of
mortality for those with clinical infections, and is a key
component of malaria elimination and eradication plans
both past and present [3]. Diminished therapeutic effi-
cacy due to the evolution of resistance to previous first-
line drugs, however, contributed to the failure of initial
eradication efforts and resulted in increases in infection
and mortality [4]. Drug stewardship, combination thera-
pies, and other policies have been advocated to slow the
evolution of resistance to anti-malarial drugs, however
to be effective, a policy must delay emergence or at least
slow the spread of resistant parasites. Combination of
drugs, such as artemisinin combination therapy (ACT),
delay emergence by eliminating resistant mutants except
those that carry two different mutations. Since each
drug can eliminate mutants that are resistant to the
other component, mutations to both components must
arise in the same parasite. Combination therapies thus
delay the time until a viable resistant parasite appears
[5]. Alternative strategies call for reducing selection for
the spread of resistance by using drugs more prudently
or by rationing drugs [6]. Such strategies assume that
the rate of spread increases in proportion to the rate of
drug use in a population. Multiple first-line therapies
(MFTs) on the other hand, reduce pressure on each
drug, defined as the proportion of clinical episodes that
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problem of leaving some patients untreated [7,8].
While combination therapies delay emergence and
MFTs slow spread, this simple analysis ignores the other
effects of reducing drug pressure. Emergence itself is a
complicated process that begins with random mutations
and drug treatment, followed by transmission and sto-
chastic persistence until a mutation(s) conferring resis-
tance has become firmly established in the population.
Mutations that confer drug resistance can arise any time
a parasite replicates, but drugs must reduce the density
of drug-sensitive parasites to allow resistant parasites to
thrive within a human and have a reasonable chance of
being transmitted to another human (Figure 1, top) [9].
Appearance of resistance is the result of within-host
selection of a new mutant, not just mutation, so the rate
of appearance is proportional to drug pressure.
De novo resistant mutants may fail to become estab-
lished, as the parasite is present in only a few hosts, and
thus its persistence is a matter of chance [10,11] (Figure
1, middle). The fitness advantage for drug-resistant
parasites under some level of drug pressure is partially
offset by a fitness disadvantage, or a biological cost of
resistance, if drugs are absent [12-15]. The biological
cost will tend to be highest when resistance first appears
and will reduce the probability of establishment because
mutations that lower fitness tend to die out [12,13].
Therefore, reducing drug pressure would also reduce
the chances of establishment by increasing the effect of
a high initial cost of resistance.
Thus, reducing drug pressure impacts the evolution of
resistance in three ways: it delays its appearance, reduces
the likelihood of its establishment, and slows its spread
(Figure 1, bottom). However, the evolution of drug resis-
tance involves complex nonlinear processes, and thus
substantial uncertainty exists about the relative impact
of deploying MFTs because of unknown mutation rates,
poor information about drug pressure, and a poorly
defined relationship between drug pressure and fitness.
Weighing uncertainty requires a quantitative approach
using mathematical models. In this paper, the effective-
ness of deploying multiple ACTs to manage resistance
was evaluated using a hybrid modelling approach that
weighs all three potential benefits of deploying MFTs.
Methods
Most new first-line anti-malarial drugs as well as most
anti-malarial drugs in the development pipeline contain
an artemisinin-class drug. To extend their useful thera-
peutic lives, artemisinins are paired with a partner drug
and given as combination therapies. While several differ-
ent ACTs are already available on the market, artemisi-
nin monotherapy is still readily available in many places.
Cross-resistance among all the artemisinin derivatives is
expected, and the evolution of resistance to a partner
drug should be comparatively easy for a parasite with
artemisinin resistance, so the loss of one ACT would
probably lead to the rapid loss of all ACTs. Because new
non-artemisinin anti-malarial drugs will likely not be
available for a decade or more, preserving artemisinin is
crucial. A significant threat to artemisinin comes from
the evolution of resistance to the partner drugs, whose
pharmacokinetic half-lives are generally significantly
longer than the artemisin-class drugs they are paired
with. This has led to concerns about selection for part-
ner drug resistance after the artemisinin concentrations
have waned [5,16]. MFTs would provide one way for the
partner drugs to protect each other and, by extension,
artemisinin. To examine the full benefit of MFTs, a
quantitative approach to assessing the waiting time to
ACT failure was developed.
Appearance
Appearance, defined as an infection with de novo
mutants that are frequent enough within a single host
to be transmitted to another host, requires a resistant
mutant and treatment (Figure 1, top). The probability
that at least one resistant mutant is present when
chemotherapy begins is determined by the probability
of spontaneously generating a resistant mutant per
cell division, m, and the parasite population size at
the time of treatment, P. The probability of appearance
is thus approximately mP (assuming it is small, i.e.
mP < 0.01).
The time to appearance, Ta, in a human population of
size H depends on the distribution of parasite
population sizes at the start of treatment, Y(P). De novo
resistance appears with some low probability each time
a person is treated: ∫ mP Y(P) dP.T h ew a i t i n gt i m e
to appearance also depends on the number of people
who are treated which depends on per-capita clinical
incidence L, the human population size, H,a n dd r u g
pressure, or the proportion of clinical episodes that
are treated, p; the number of clinical episodes that are
treated per year is thus pLH. The waiting time to
appearance is exponentially distributed with mean:
TY a pLH mP P dP
− = () ∫
1 .
Given an estimate of the mutation rate and the distri-
bution of parasite population sizes, it is possible to com-
pute the expected number of people who could be
treated before resistance would appear once (Figure 2).
Time to appearance is inversely proportional to human
population size and drug pressure: if the number of
people taking a drug is cut in half, then the expected
waiting time to emergence is twice as long. Human
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Page 2 of 10Figure 1 The evolution of anti-malarial drug resistance. The evolution of anti-malarial drug resistance is shown schematically in three steps:
Top) Appearance involves de novo mutation and within-host selection by drugs (brown). Sensitive parasites (black) initially outnumber resistant
mutants (red), but after treatment, the proportion of parasites that are resistant (blue) increases, and so too does the likelihood of transmitting a
resistant parasite. Middle) Emergence involves sporadic appearance (red) and stochastic establishment. Establishment involves generating
“progeny” (infected humans) and becoming common enough to avoid stochastic fadeout. In the generations after appearance, the number of
progeny fluctuates. This was simulated as an evolving branching process and illustrated with vertical lines whose thickness corresponds to the
number of progeny in that generation. In the figure, the last one successfully established, defined as a point when 100 “offspring” existed with
positive fitness, and spread was considered virtually certain. Bottom) After emergence, the spread of resistance was simulated in simple
epidemiological models. Starting from 100 individuals who carried resistant parasites, the time to failure (10%, dashed line) depended strongly
on the human population size (H).
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Figure 2 The waiting time to appearance. Top) The waiting time to appearance in a treated individual is plotted against the mutation rate for
a range of parasite densities. Horizontal lines mark the point where exactly one appearance is expected in treated populations of different size.
Bottom) Colors encode categorical descriptions of the time to appearance for parameters that span the relevant range for the number of people
treated in one year and the probability of appearance, per treatment. In both panels, the red lines are centered on a mutation rate of 10
-17.2 (i.
e., two independent mutations at the rate for mutations that confer SP resistance), parasite densities of 10
10, and 1 billion treatment courses per
decade. The lines span parasite densities from 10
9 to 10
11 and global demand from 100 million to 5 billion.
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Page 4 of 10population size is not like the other parameters in that
the choice of H, up to the global population at risk [17],
defines the scale of the problem being considered.
Establishment
After appearance, a parasite can only become estab-
lished by spreading to other hosts. Parasite fitness is
measured in terms of the replacement number, the
expected number of human hosts that would be infected
for each human host infected. The fitness of a resistant
phenotype is determined by its biological cost and by
the advantage conferred from drug pressure. If a para-
site cannot replace itself, it will never become estab-
lished, though parasite fitness may be too low for it to
become established initially. The fitness of a resistant
phenotype will tend to increase if they persist, as they
can acquire compensatory mutations to overcome the
biological cost of resistance. Both persistence and the
acquisition of compensatory mutations are chance
events, though the compensatory mutations increase the
likelihood of persistence.
Establishment of resistance was considered in a popu-
lation where malaria is endemic, and where on average
parasites replace themselves approximately once. Para-
sites with de novo resistance are rare in a population
when they first appear, by definition, and when replace-
ment numbers are close to one, they frequently fail to
establish.
The probability of establishment, Q,a n dt h en u m b e r
of parasite generations required to establish, G,w e r e
estimated by simulating an evolving branching process
[10,11,18]. A branching process does not keep track of
when the progeny were produced, but rather the num-
ber of offspring in each generation that has elapsed (Fig-
ure 1, middle). The number of “offspring” (i.e., new
human infections) was drawn from a negative binomial
distribution to account for heterogeneous biting [19,20].
The offspring evolved by inheriting a slightly different
fitness than their parents. The branching process was
iterated until no parasite offspring remained (a failure)
or there were at least 100 offspring with replacement
numbers greater than one (a success) (Additional file 1).
It was repeated n times until there were s successes, and
Q ≈ (s-1)/(n + s-1). Assuming that the time required to
complete a parasite generation was Tg (i.e. the average
time from one human infection to another, at least one
month and generally approximately two months), the
waiting time to emerge was
TT Q G T ea g =+
Failure to establish has the effect of delaying emer-
gence as much as requiring an additional mutation that
occurs with frequency Q.
There is always some chance that a parasite would fail
to establish, but establishment was most unlikely when
the fitness was initially lower than 1 (Figure 3). The
probability of establishment was also directly related to
the maximum attainable fitness. As the maximum
attainable fitness fell, so too did the probability of estab-
lishment. Reducing drug pressure would lower both the
initial and maximum attainable fitness. When the initial
fitness was 0.7 (measured as relative to the sensitive
parasite) and asymptotic fitness was 1.05, approximately
one mutant per million would establish (i.e., Q ≈ 10
-6).
The analysis also suggested, not surprisingly, that more
generations were required for establishment when either
initial or asymptotic fitness was lower. In those parasites
that did become established, the number of generations
Figure 3 Summary statistics from the evolving branching
process for a Poisson distribution. Top) The probability of
establishment (colors) was plotted as a function of the maximum
replacement number and the initial replacement number. For the
range of values plotted here, the probability of establishment
ranged from 1 in 10 to 1 in a million. Bottom) The number of
generations that elapsed before successful establishment, plotted
for the same fitness values, ranged from 12 to 80.
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Page 5 of 10that elapsed prior to establishment ranged from 12 to
80, a delay of two to seven years.
Spread
The spread of resistance was simulated using a simple
epidemiological model that describes the dynamics of
malaria. The models consider the fraction of humans in
a population who are asymptomatically infected with
drug-resistant or drug-sensitive parasites, x or w, respec-
tively (Figure 1, bottom). The models also consider the
incidence of clinical malaria in relation to infection sta-
tus in a very general way (Additional file 1).
A therapy was considered to have “failed” when the fre-
quency of resistance (i.e. x/(x + w)) exceeded a predefined
threshold; the WHO threshold of 10% was adopted. The
end of the branching process was the starting point for
the epidemiological model, so in a population of H
humans, the initial frequency of resistance was 100/H
humans. The time to reach a frequency of 10% was
longer in larger human populations where the initial
frequency was lower (Figure 1, bottom).
Results and Discussion
Reducing parasite fitness
To illustrate how multiple first-line therapies would
reduce resistant parasite fitness, the reductions in drug
pressure achieved using an MFT policy was compared
to a drug rationing policy. The fitness of resistant
phenotypes in a population that uses two first-line
therapies was similar to the fitness of resistant pheno-
types with a single first-line therapy where half as many
people were treated and cured (Figure 4). This was not
surprising, since the point of an MFT is to treat half the
patients with one drug while treating the other half of
the population with a different drug.
Reducing drug pressure and time to failure
The expected waiting time to drug failure, denoted TF,
considers appearance, establishment, and spread:
TTT Fe =+ 10%.
Reducing drug pressure delays appearance, reduces the
likelihood of establishment, and slows spread. The
expected waiting time to appearance was exactly twice
as long when drug pressure was cut in half (Figure 5,
top). The waiting time to establishment was approxi-
mately twice as long, too, through a combination of
delayed appearance, an increase in the number of gen-
erations required to establish, and an increased likeli-
hood of stochastic fadeout.
Reducing drug pressure also slows the spread of resis-
tance. The benefits of extending a policy are compli-
cated because of a threshold on drug pressure, a tipping
point that favors drug-sensitive or drug-resistant para-
sites (Additional file 1). If reducing drug pressure takes
selection from one side of the tipping point to the
other, then it would delay drug failure indefinitely (Fig-
ure 5b). The quantitative benefits of reducing drug pres-
sure, however, are much lower if selection stays on the
same side of the tipping point. If drug pressure were
low enough that drug-sensitive parasites were favored,
there would be no need to reduce drug pressure further.
If drug pressure were sufficiently high that it favored
drug-resistant parasites before and after adopting a pol-
icy, reducing drug pressure would approximately double
the time to failure (Figure 5b).
Decisions to preserve the efficacy of anti-malarial
drugs are often made over a finite time horizon; here,
the goal was preserving drug efficacy over 20 years. The
introduction of a finite time horizon for planning is
similar to the analysis of tipping points. If the goal of a
policy is to preserve a drug for at least 20 years, then
the analysis must reduce drug pressure low enough to
achieve this goal. If the waiting time to failure for a sin-
gle ACT were longer than 20 years, then there would be
no need to do anything. A maximum benefit of deploy-
ing MFTs is found when a single ACT would delay
resistance by about a decade. The plot of years gained
up to a maximum of 20 years plotted against drug pres-
sure, has the shape of a shark fin (Figure 5b). The com-
bined effects of delayed emergence and delayed spread
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Figure 4 A comparison of parasite fitness under strategies of
rationing drugs to treat 50% of cases vs. two first-line ACTs.
This figure assumes that baseline drug pressure is 40% and that the
biological cost is 10%. The waiting time to clinical malaria (i.e. any
fever) in those with infection (x-axis) and the proportion of new
infections that present with clinical symptoms (y-axis) span the
relevant values for malaria. When the profile for clinical malaria
resembled low-transmission settings, the benefits of MFTs were
slightly lower than treating half as many patients. When the profile
resembled high-transmission settings, MFTs did slightly better than
rationing drugs. The colors shade in different categorical
descriptions of the ratio. For most values, the ratio is within 5% of 1
(light gray).
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Page 6 of 10all combine to extend the useful therapeutic life of a
drug (Figure 5c).
The most important principle is that the benefits of
implementing a policy in terms of a waiting time to
failure are all proportional to the waiting time to fail-
ure in the absence of any policy. It follows that a pol-
icy to preserve a drug is worth implementing only if
the waiting time to fail is in the right range; if the
waiting time to fail is less than one year, then a policy
must extend the useful life of a drug by a factor of 20
or more, a practical impossibility. If the drug already
has a waiting time of more than 20 years, then a policy
is not really necessary. This principle transcends the
uncertainty and makes it possible to say something
more concrete about which drugs are worth protecting
with a policy.
Uncertainty and scale
The time to failure depends on the drug pressure, the
mutation rates, the biological cost of resistance over
time, the clinical incidence, and the generation time of
the parasites. There is substantial uncertainty about all
these parameters. To weigh the value of deploying
MFTs, a probability distribution function was assigned
to the parameters to compute times to failure (Addi-
tional file 1). The answers were generally uninformative.
Because there was so much uncertainty in all of the
parameters, a slightly different question was asked:
when would MFTs be most likely to provide a benefit?
Asking the question in this way and doing a sensitivity
analysis showed that the scale of the question was a
dominant factor in the analysis; the more people with
parasites who were treated, the shorter the time to
appearance, but the longer the waiting time to reach a
frequency of 10% because of a smaller initial frequency
of resistance. The question of the appropriate scale
came to dominate the analysis when it was noted that
reducing the scale could increase the waiting time to
appearance by millennia, depending on the size of the
population at risk. Given the potential for ACT resis-
tance to emerge anywhere and spread to nearly every-
where, as was the case with resistance to chloroquine
and sulfadoxine-pyrimethamine [21], the global scale
was considered to be appropriate.
Parasite population density at the time of treatment can
vary by several orders of magnitude, which has a strong
effect on the probability of appearance. Clinical malaria
in an immunologically naïve adult can produce parasite
densities that range up to 10
12 parasites, in extreme
cases. In areas with highly endemic malaria and clinical
immunity, adults tend to have less clinical malaria with
lower parasite densities at the time of treatment. By com-
parison, children are often immunologically naïve, but
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Figure 5 Reducing drug pressure will delay emergence and
slow spread. The benefits of halving drug pressure can be
enormous, but they must be considered within a finite time horizon.
The x-axis shows baseline drug pressure. Baseline waiting times are
plotted in blue. Baseline waiting times for halving drug pressure are
plotted in red. The net benefit (the difference) is plotted in black.
Top) Time to emerge (solid lines) combines the time to appear
(dashed lines) with stochastic establishment. Middle) Clinical efficacy
would be preserved for 20 years if drug pressure were low (red).
Reducing drug pressure (blue) has a benefit in an intermediate
range–when drug pressure is not low enough to make an
intervention necessary but not high enough that resistance will
rapidly fix, even if reduced. Bottom) For a reference parameter set,
the combined effects of delaying emergence and slowing spread
guarantee that MFTs will last 20 years. For high baseline drug
pressure, the estimated waiting time to failure was as low as 5 years.
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Page 7 of 10they have less blood volume and a smaller number of
parasites. Reasonably large parasite population sizes were
considered (assuming 10
9 <P<1 0
12).
The probability of appearance in an individual is
extremely low, thus the waiting time to emergence
somewhere in the world must account for the large
populations at risk and global demand for drugs. There
are approximately 450 million clinical malaria episodes
per year, with a credible range of 350-550 million cases
[22]. If ACT were scaled up to meet global demand,
there could be as many as 5 billion courses of ACT per
decade. For a single combination therapy to delay the
appearance of resistance by a decade, assuming that 1
billion people were treated over a decade, the probability
a resistant mutant appears per treatment would have to
be less than approximately 10
-18.
Mutation rates in the dihydrofolate reductase gene
of P. falciparum are estimated to be approximately
2.5 × 10
-9 [23]. If ACT resistance required two such
mutations of similar frequency, the mutation rate
required for resistance to an ACT would be closer to
10
-17. By this arithmetic, the waiting time to appearance
somewhere in the world is close to a year. For a refer-
ence set of parameters (Additional file 1), the estimate
of the waiting time to failure, after scaling up ACT, was
approximately eight years. There was, it should be
recalled, very little confidence in this particular estimate.
One notable feature of this analysis was that it com-
bined very small numbers (mutation rates) with very
large numbers (parasite population densities, the global
demand for anti-malarial drugs). A small change in one
of the exponents could change the time to failure by a
factor of 10 or more. The proportional changes that
w o u l db ea c h i e v e db yi m p l e m e n t i n gM F T sw e r em o s t
important for policy when the waiting times were large
enough to have a noticeable effect but not already suffi-
c i e n tt op r e s e r v eA C T sf o r2 0y e a r s .C u r i o u s l y ,w h e n
the big numbers were combined, they roughly balanced,
and the waiting time to appearance, at a point in time
when ACTs are the de facto global first-line treatment
for malaria, would be close to one year, precisely the
value where MFTs would have maximum benefit. As an
example, MFTs delayed the waiting time to failure from
8 to 17 years (Figure 2).
Conclusions
Treating fewer patients would likely reduce selection
pressure and slow the spread of resistance, but there are
few practical ways of reducing drug pressure without
putting lives at risk. MFTs are one way: treating half the
population with one ACT and the other half with a
different ACT would reduce the fitness of resistant para-
sites approximately as well as treating half as many
patients [8]. A simple rule of thumb for deciding
whether to choose MFTs is that if there is an advantage
to cutting drug pressure by half or more, then there is
an advantage to deploying two or more ACTs.
This analysis suggests that MFTs are deployed to best
effect on different segments of the same population.
One possibility would be to distribute one ACT for
home-based care and use a different ACT in the clinic.
Another promising strategy would partition the market
by age: paediatric patients would be given one ACT,
adults another. The paediatric and adult markets are
already partitioned because adults and children require
different formulations. Implementing MFTs would
introduce operational challenges, but choosing different
first-line ACT for paediatric and adult populations
would work as a solution within a set of operational
challenges that already exist.
MFTs are deployed to best effect before resistance
emerges, but such decisions must be made in the face of
massive uncertainty. Despite uncertainty, a strategic
policy decision to protect artemisinin by promoting uni-
versal use of ACT has been proposed and partially
implemented [24]. If mutation rates for artemisinin
resistance were known, the waiting time to the global
emergence of ACT resistance could be calculated with
increased confidence, and it would then be possible to
evaluate whether existing policies were adequate.
Recently, stable artemisinin resistance has been demon-
strated in a murine model [25] and artemisinin-resistant
infections were described along the Thai-Cambodia bor-
der [26] where artemisinin-class drugs have been used
in Southeast Asia for twenty years [27]. While, the rate
that artemisinin resistance spontaneously appears is
apparently low, its emergence as usage rates dramati-
cally increased raises the question of if it is low enough
to preserve ACT until a new class of anti-malarial drugs
is available? The answer will not be known with confi-
dence until after ACT resistance has fully emerged.
Meanwhile, uncertainty will remain high.
Surprisingly, this analysis arrived at a robust conclu-
sion despite the epidemiological and biological uncer-
tainties. In small and isolated populations, combination
therapies could have a huge benefit by delaying the time
to appearance, so the benefit of MFTs would be com-
paratively small. In the global human population at risk
of malaria, the enormous benefits of combination thera-
pies shrank because ACT resistance could emerge any-
where and spread everywhere, and the relative benefits
of delaying establishment and spread using MFTs were
comparatively large.
Our study suggested that, with wide confidence inter-
vals, the waiting time to the global emergence of resis-
tance to ACT was approximately a decade. MFTs would
provide some insurance against this calamity by delaying
emergence further and then slowing the spread of
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Page 8 of 10resistance. The same logic would support a triple com-
bination–three drugs given simultaneously, resistance to
which requires three independent mutations. A triple
combination would almost certainly delay the appear-
ance of resistance by a decade or more if the genetic
basis for resistance to all three components were
mutually independent, but no such therapy is available
today.
In retrospect, the results reflect that ACT resistance is
unlikely to appear in any small population, but it will
appear with virtual certainty in a large one, thus slowing
spread has a comparatively large benefit at the global
scale. Variability in drug pressure among populations
would likely depend on access to health care, the level
of clinical immunity, and socioeconomic status. The
populations of the world can be considered a mosaic of
sources and sinks for resistance, depending on whether
resistance is favoured or not. In such a landscape, MFTs
will shift the balance and increase the proportion of
sinks that would naturally contain ACT resistance.
Combination therapies are designed to make appearance
a truly rare event, but if they don’tw o r ka sw e l la s
intended, MFT strategies provide an insurance policy by
delaying emergence further and by limiting spread after
emergence. MFTs are thus a natural complement to
combination therapies.
Combination therapies for malaria were adopted in
the face of uncertainty. The basis for deploying artemisi-
nin combination therapies comes mainly from ap r i o r i
arguments about mutation rates and from experience
with other drugs, such as the success of the combination
drug sulphadoxine-pyrimethamine over pyrimethamine
alone. The case for MFTs must be made on the same
basis as the case for combination therapies but with a
greater degree of uncertainty. Since the loss of artemisi-
nin would likely result in the loss of all ACTs, existing
ACTs must be used in the best possible way. Despite
the uncertainty, the analysis makes a strong ap r i o r i
case for a coordinated global policy, like the global sub-
sidy for ACTs, to promote heterogeneous drug policies
to ensure the long-term therapeutic efficacy of ACTs.
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